Interested in owning StemCellPatents.com? Contact info@stemcellpatents.com.
Patents (1436 Stem Cell Patents)

Modulation of stem and progenitor cell differentiation, assays, and uses thereof

Patent Number: 7,498,171

Date of First Priority Issue: Friday April 12th, 2002
Date Issued: Tuesday March 3rd, 2009
Assignee: Anthrogenesis Corporation (Warren, NJ)
Inventors: Hariri; Robert J. (Florham Park, NJ), Stirling; David I. (Warren, NJ), Moutouh-De Parseval; Laure A. (San Diego, CA), Chan; Kyle W. H. (San Diego, CA)

From Class: Differentiation
Comments: No comments

One of the areas in which regenerative medicine is heading is the use of "drugs" to modulate the stem cell compartment.  For example, we have previously seen companies like Stem Cell Therapeutics performing clinical trials with EPO and hCG for stroke.  Drugs already in the clinic such as Velcade, have also been reported to affect the stem cell compartment

The current patent covers the use of various thalidomide analogues for preferentially stimulating hematopoietic stem cell (CD34 and CD133) differentiation along the myeloid pathway but not the erythroid pathway.  Interestingly the claims cover both in vitro and in vivo manipulation. 

In the first independent claim the patent covers "A method for promoting the differentiation of mammalian CD34+ or CD133+ hematopoietic stem cells to CFU-GM (colony-forming units-granulocyte/macrophage) while inhibiting their differentiation to BFU-E (blast-forming units-erythrocyte), said method comprising: contacting said stem cells with an amino-substituted thalidomide analog under conditions under which said stem cells differentiate, wherein the amino-substituted thalidomide analog is selected from the group consisting of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, and wherein said contacting detectably increases the number of CFU-GM and detectably decreases the number of BFU-E differentiated from said stem cells relative to the numbers of CFU-GM and BFU-E differentiated from mammalian CD34+ or CD133+ hematopoietic stem cells not contacted with said amino-substituted thalidomide analog. "

Various thalidomide analogues have been previously reported by Kyle Chan's group from Celgene to manipulate the hematopoietic compartment, for example in this JCI paper, thalidomide analogues pomalidomide and lenalidomide were found to synergize with hydroxyurea for stimulation of fetal hemoglobin production. 

It will be interesting to see if these compounds affect other stem cell compartments as well, such as endogenous cardiac or neural stem cells.

View this patent on the USPTO website.

Added to StemCellPatents.com on Monday March 9th, 2009

Social & Bookmarking:Digg 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to del.icio.us Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Technorati Stumble 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Furl Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Reddit Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Blinklist Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Ma.gnolia Share 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' on Facebook Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Google Add 'Modulation of stem and progenitor cell differentiation, assays, and uses thereof ' to Yahoo Web 

Add Comment

You must be signed-in to add your comments.

Sign-in now or Join the StemCellPatents.com Community for free.



Home | News | Patents | Products | Jobs | Links | Search | Journal | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2020 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.10